Looking to read the full article? Subscribe to BioWorld.

Synendos raises $21.8 million, targets CNS conditions via endocannabinoid system

November 12, 2020

LONDON – Synendos Therapeutics AG is poised for a fresh attempt at drugging the endogenous endocannabinoid system after raising CHF20 million (US$21.8 million) to take its lead program into clinical development.

BioWorld Financings Neurology/Psychiatric

Already a subscriber? Sign in

Today's news in brief

BioWorld

BioWorld briefs for Nov. 25.

Today's news in brief

BioWorld MedTech

BioWorld MedTech's briefs for Nov. 25.

Lucira Health wins FDA nod for first completely in-home COVID-19 test

BioWorld MedTech

Lucira Health Inc. has secured U.S. FDA emergency use authorization for the first prescription molecular diagnostic test for COVID-19 that can be performed from...

Other news to note for Nov. 24, 2020

BioWorld

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbreos, Allero, Almirall, Alvotech, Astrazeneca,...

Seed Therapeutics blossoms in an $800M deal with Lilly

BioWorld

Seed Therapeutics Inc. signed a massive deal with Eli Lilly and Co. on Nov. 12, a date that resonated deeply with Seed’s CEO, Lan Huang. Twenty-one years earlier...